Wikipedia -WSS

Wikipedia

author：fashion 2025-09-28 23:11:50 - browse：625

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： The most pressing bird flu mysteries scientists want answered

leisure time

WSS

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

As obesity drug market grows, telehealth companies court payers

FDA advisory panel to debate high blood pressure devices

The most pressing bird flu mysteries scientists want answered

Hospital at home shows how to bring innovation to health care

Wikipedia

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Peter Hotez and the public health issue of online harassment

FDA advisory panel to debate high blood pressure devices

Cancer drug shortages should be causing more outrage

Can U.S. cancer drug shortages be fixed?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Hepatitis C has a cure — but many Americans still lack access to it

California store owner shot dead in dispute over displaying Pride flag: Police

Activists slam private health insurers over coverage restrictions

BD to buy Edwards patient monitoring unit for $4.2 billion

focus

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Roche's accidental data boosts hopes for anti

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

FTC loses bid to block Novant's North Carolina hospital merger

Data don't support strong claims for Covid

hotspot

focus

leisure time

focus